DIM Stock Overview
Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €164.25 |
| 52 Week High | €286.30 |
| 52 Week Low | €139.10 |
| Beta | 0.64 |
| 11 Month Change | 4.05% |
| 3 Month Change | -21.15% |
| 1 Year Change | -41.82% |
| 33 Year Change | -65.87% |
| 5 Year Change | 15.18% |
| Change since IPO | 1,898.58% |
Recent News & Updates
Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 21
Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Jul 12Recent updates
Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 21Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Jul 12Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet
May 13Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next
Apr 21With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For
Apr 20Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)
Feb 19Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear
Dec 22Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
Dec 01Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Nov 10Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Aug 23Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly
May 25Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Is Well Worth Watching
May 09Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Apr 23Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Feb 07Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?
Jan 20Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet
Nov 09Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today
Oct 20Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Oct 03We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt
Jul 26Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?
Jul 09Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 21Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt
Apr 21Here's Why I Think Sartorius Stedim Biotech (EPA:DIM) Is An Interesting Stock
Apr 03We Like Sartorius Stedim Biotech's (EPA:DIM) Earnings For More Than Just Statutory Profit
Feb 24Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Dec 04Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt
Aug 21Shareholder Returns
| DIM | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 11.8% | 0.5% | -2.4% |
| 1Y | -41.8% | -14.6% | -4.7% |
Return vs Industry: DIM underperformed the French Life Sciences industry which returned -14.6% over the past year.
Return vs Market: DIM underperformed the French Market which returned -4.7% over the past year.
Price Volatility
| DIM volatility | |
|---|---|
| DIM Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.5% |
Stable Share Price: DIM's share price has been volatile over the past 3 months.
Volatility Over Time: DIM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,382 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| DIM fundamental statistics | |
|---|---|
| Market cap | €15.98b |
| Earnings (TTM) | €169.50m |
| Revenue (TTM) | €2.75b |
94.3x
P/E Ratio5.8x
P/S RatioIs DIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIM income statement (TTM) | |
|---|---|
| Revenue | €2.75b |
| Cost of Revenue | €1.56b |
| Gross Profit | €1.19b |
| Other Expenses | €1.02b |
| Earnings | €169.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 17, 2024
| Earnings per share (EPS) | 1.74 |
| Gross Margin | 43.16% |
| Net Profit Margin | 6.17% |
| Debt/Equity Ratio | 71.7% |
How did DIM perform over the long term?
See historical performance and comparison